Study on Polatuzumab Vedotin, Rituximab, and Reduced Dose CHP in Older Patients with DLBCL

Sponsor: University of Rochester

Sponsor score: 0

ClinicalTrials ID:NCT04594798

Provider View

This clinical trial is testing the safety and effectiveness of a new treatment combination for patients aged 75 and older with Diffuse Large B-Cell Lymphoma (DLBCL). The treatment includes polatuzumab vedotin, rituximab, and a reduced dose of chemotherapy drugs.

Patient Parameters

Program Overview

The purpose of this study is to see if adding polatuzumab vedotin to a treatment plan that includes rituximab and a reduced dose of chemotherapy drugs (R-miniCHP) is safe and effective for patients aged 75 and older with Diffuse Large B-Cell Lymphoma (DLBCL).

Description

In this study, researchers want to understand how well polatuzumab vedotin works when added to a treatment plan with rituximab and a reduced dose of chemotherapy drugs (R-miniCHP) in patients aged 75 and older. The study will look at the safety and effectiveness of this combination in treating DLBCL, a type of aggressive lymphoma. Participants will receive the treatment and be monitored for any side effects and how well the cancer responds.

Eligibility Criteria

Inclusion Criteria

  • Must be 75 years or older.
  • Must have a confirmed diagnosis of DLBCL or related types of lymphoma.
  • Must not have received prior treatment for aggressive B-cell lymphoma, except for certain allowed medications.
  • Must not be a candidate for standard dose R-CHOP due to age or other health conditions.
  • Must have a heart function of at least 45%.
  • Must have adequate blood cell counts and organ function.
  • Men must agree to use contraception during treatment and for 5 months after.

Exclusion Criteria

  • History of lymphoma affecting the brain or spinal cord.
  • Specific types of lymphoma like primary mediastinal B-cell lymphoma.
  • Currently on dialysis.
  • Severe nerve damage.
  • Severe heart failure or low heart function.
  • Recent use of other experimental drugs.
  • Previous treatment with anthracycline, except for one urgent cycle.
  • Other active cancers that may interfere with the study.
  • Known HIV positive status.
  • Active hepatitis B infection.
  • History of organ or stem cell transplant.
  • Serious medical or psychiatric conditions that may affect participation.

Locations

FACILITYZIPCITYSTATE
University of Rochester14642RochesterNew York

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.